Latham & Watkins Advises on Oviva’s US$80 Million Series C

Latham & Watkins advised the lead investor on its Series C investment in Oviva, a health tech startup. Oviva’s US$80 million Series C funding brings its total raised to date to US$115 million.

Oviva combines expert advice from dietitians with digital tools to help people with conditions such as type 2 diabetes improve their health. Oviva will use the new capital to scale up its business.

The Latham team was led by London partner Mike Turner and associate Samantha Si.